FL-BACARDI-LIMITED
4.2.2020 13:17:10 CET | Business Wire | Press release
This Thursday, 7,000 Bacardi employees across the globe will turn on their “out of office” message to go out on the town and visit bars in more than 100 cities, all in the name of spotting what’s new and next for cocktails. The activity, called Back to the Bar, brings everyone at Bacardi together for a day of “barstool research” with bartenders who are the trend spotters and tastemakers of the spirits business and a direct link to consumers. According to Nielsen CGA, 40% of revenue in bars is influenced by bartenders as they are the go-to experts to help you pick your drink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005256/en/
As part of the third iteration of Back to the Bar, the largest privately-held spirits company sheds light on what's creating excitement for bartenders with the release of the Bacardi 2020 Cocktail Trends Report. The report highlights trends based on insights captured from a survey Bacardi ran with bartenders and bar ambassadors in 2019, as well as third-party research from the world’s leading consumer insights firms.
"Back to the Bar tradition is a time when everyone across the company, regardless of day job, becomes an ambassador and a researcher by going back to where our business is made – the local bars and restaurants," says Mahesh Madhavan, CEO of family-owned Bacardi Limited. "We are in the relationship business and I never miss an opportunity to talk to a bartender or our consumers to learn what they’re seeing and what they think will be the next big thing.”
As the company celebrates its 158th anniversary this week, Back to the Bar also commemorates the company’s legacy of a founder’s mentality and entrepreneurial spirit. For seven generations, the family-owned business has instilled a belief that brands are built in bars, not boardrooms. Everyone at Bacardi participates in this “roll-up your sleeves” approach to data collection and serves as influencers by talking to friends, family, and consumers about the brands.
“In an era where people are flooded with data, there is no substitute for putting feet on the street and seeing first-hand what’s happening at the bar," says Jacob Briars, Global Advocacy Director at Bacardi. “When something excites the bartenders, we know that it is a matter of time before we start to see a shift in the mindset and behavior of our guests.”
Among the findings of the Bacardi 2020 Cocktail Trends Report are that:
- Mindful drinking goes mainstream, with 83% of bartenders citing that low-alcohol drinks are hot and an increase of 42% in the online searches with the word 'mocktail' in 2019. (Technomic Behind the Bar Insights, 2019 and Google Trends, 2019)
- Natural products are in the spotlight with 31% of bartenders increasingly interested in local, fresh ingredients. (Global Brand Ambassador Survey (GBAS), 2019)
- The culinary cocktail trend borrows methods and techniques from the kitchen and champions fresh, seasonal, savory and herbal ingredients – 91% of bartenders use vegetables in their cocktails, and 68% of American Culinary Federation members rated culinary cocktail as a 'hot trend' last year. (Technomic Behind the Bar Insights, 2019)
- Dark rum is leading the premium game – 43% of bartenders ranked it as the top spirit to premiumize. (GBAS, 2019)
- Sustainability is at the forefront of every consumer's mind, and it's reflected in the bar – 66% of bartenders mention that sustainable drinks are hot right now. (Technomic Behind the Bar Insights, 2019)
- Ready-To-Drink (RTD) cocktails are here to stay, reflecting the overarching demand for consistent and convenient well-crafted cocktails beyond the bar – there was a 26% increase of vodka soda and flavored RTDs in North America last year. (GBAS, 2019)
- 38% of Americans prefer to make their cocktails at home, and the industry has quickly adapted, offering consumers myriad ways to facilitate at-home imbibing, from home cocktail kits to AI-recommended recipes. (Mintel, 2019)
Click here to access the complete Bacardi 2020 Cocktail Trends Report .
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates more than 20 production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Instagram , LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
